Flupyranochromene, a novel inhibitor of influenza virus cap-dependent endonuclease, from Penicillium sp. f28743.


Journal

The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115

Informations de publication

Date de publication:
03 2019
Historique:
received: 04 10 2018
accepted: 30 11 2018
revised: 12 11 2018
pubmed: 10 1 2019
medline: 30 4 2019
entrez: 10 1 2019
Statut: ppublish

Résumé

Influenza virus RNA polymerase has cap-dependent endonuclease activity that produces capped RNA fragments for priming viral mRNA synthesis. This enzymatic activity is essential for viral propagation, but it is not present in any host cellular enzyme, making it an attractive target for the development of anti-influenza drugs. Here, we isolated a novel inhibitor of cap-dependent endonuclease, named flupyranochromene, from the fermentation broth of the fungus Penicillium sp. f28743. Structural analysis revealed that this compound bears a putative pharmacophore that chelates divalent metal ion(s) present in the endonuclease active site in the PA subunit of the polymerase. Consistently, in vitro endonuclease assays showed that flupyranochromene exerts its inhibitory effects by blocking endonucleolytic cleavage by the PA subunit of viral RNA polymerase complex.

Identifiants

pubmed: 30622294
doi: 10.1038/s41429-018-0134-z
pii: 10.1038/s41429-018-0134-z
doi:

Substances chimiques

Antiviral Agents 0
Enzyme Inhibitors 0
PA protein, influenza viruses 0
Viral Proteins 0
RNA-Dependent RNA Polymerase EC 2.7.7.48

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-133

Auteurs

Manabu Yamasaki (M)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan. yamasakim@bikaken.or.jp.

Masayuki Igarashi (M)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Ryuichi Sawa (R)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Chisato Nosaka (C)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Maya Umekita (M)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Masaki Hatano (M)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Tomoyuki Kimura (T)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Kiyoko Iijima (K)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Naoki Takizawa (N)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Taira Kato (T)

MicroBiopharm Japan Co., Ltd., Chuo-ku, Tokyo, Japan.

Kiyohisa Mizumoto (K)

Laboratory of Biochemistry, School of Pharmacy, Kitasato University, Minato-ku, Tokyo, Japan.

Akio Nomoto (A)

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.

Articles similaires

Animals Swine Antiviral Agents Swine Diseases Coronavirus Infections
Humans Carcinoma, Hepatocellular Liver Neoplasms Aged United States
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans
Animals Active Transport, Cell Nucleus RNA, Messenger Humans SARS-CoV-2

Classifications MeSH